NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

OTC Markets · Biotechnology · USD

OSR Health, Inc. (OSRH) Stock Analysis

OSR Health, Inc. (OSRH) is a Biotechnology stock listed on OTC Markets and quoted in US Dollar.

Last Updated: October 21, 2026

OSRH

$0.19

−$0.02 (−8.48%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare OSRH with… →

OSRH Key Statistics

As of Oct 21, 2026
Trading
Open
$0.19
Previous Close
$0.21
Day's Range
0.19–0.21
52-Week Range
0.075–0.90
Volume
20.53K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.48
Valuation
Market Cap
$6.75M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
3.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.37
Financials (FY)
Revenue (FY)
$2.91M−17.69%
Net Income (FY)
−$18.01M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
35.12M
1-Year Return
−69.02%
Dividend and dates
Avg Volume
9.59M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, OSRH closed at $0.19, −69.02% over 1 year.

OSR Health, Inc. (OSRH) has a market capitalization of $6.75M.

In fiscal 2025, OSRH reported revenue of $2.91M.

OSRH Stock Return by Calendar Year

OSR Health, Inc. (OSRH) return since Mar 2023: what $10,000 became

1 year
$10,000 $3,098
−69.02%
3 years
$10,000 $184
−98.16%
Since Mar 2023
$10,000 $190
−98.10%

If you had invested $10,000 in OSR Health, Inc. (OSRH) at the close on March 21, 2023, the earliest close on record here, it would have been worth $190 at the close on October 21, 2026: −98.10% in total, −66.87% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−65.94%
2025−95.11%
2024+9.81%
2023 (partial year)+3.96%

As of October 21, 2026.

OSRH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$2.91M−$18.01M−619.8%
2024$3.53M−$10.33M−292.6%
2023$0.00$403.78K—
2022$0.00$1.06M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$2.91M$592.91K−$18.34M−$18.01M−619.8%
2024$3.53M$811.24K−$11.69M−$10.33M−292.6%
2023$0.00$921.42K−$1.83M$403.78K—
2022$0.00$0.00−$621.32K$1.06M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

OSRH Valuation vs Biotechnology Median

Median of 608 stocks
MetricOSRHBiotechnology medianvs median
P/S ratio3.7313.300.3x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

OSR Health, Inc. (OSRH) carries a market capitalisation of $6.75M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 22 employees.

The most recent close on file for OSRH is $0.19, dated October 21, 2026. That is −$0.02 (−8.48%) against the previous close. The 52-week range on file runs from $0.075 to $0.90. The latest close sits 156.13% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $2.91M. Against the prior fiscal year total of $3.53M, that is a change of −17.69%. The same year closed with a net loss of $18.01M. Earnings per share on a trailing basis come to −0.37.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $2.91M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 3.73 times revenue. On price-to-sales that is 0.3 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.48. Annualized volatility over the trailing 3 years is 176.92%. Over the trailing twelve months the total return is −69.02%. Across 3 years the annualized return works out at −73.59%.

Growth & Income

The record shows no dividend for OSRH.

So far in 2026 the total return is −65.94%. Across the complete calendar years on file, 2024 returned +9.81% and 2025 returned −95.11%.

Peer Comparison

OSR Health, Inc. (OSRH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
OSR Health, Inc. OSRH $6.75M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. OSR Health, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About OSR Health, Inc.

OSR Health, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Europe, and Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the treatment of Wilms Tumor Protein (WT1); VXM08 for Carcinoembryonic antigen (CEA); and VXM10 for PD-L1. It is also developing design-augmented (DA) biologics comprising DRT-102, a clinical-stage asset for spinal fusion; and DRT-101, a pre-clinical stage asset for osteoarthritis. In addition, the company distributes neurovascular intervention medical device and systems. The company was formerly known as OSR Holdings, Inc. and changed its name to OSR Health, Inc. in June 2026. OSR Health, Inc. was incorporated in 2020 and is based in Bellevue, Washington.

Visit website →